Filtered By:
Specialty: Neurology
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 127 results found since Jan 2013.

The Need for a Coagulation Assay after Initiation of New Oral Anticoagulants in Patients with Renal Dysfunction: A Case Report.
CONCLUSIONS: The present case emphasizes the need for frequent checking of renal function and assessment using coagulation assays after commencing dabigatran therapy in patients with moderate-to-severe renal impairment. PMID: 25749821 [PubMed - as supplied by publisher]
Source: Journal of Clinical Neurology - March 11, 2015 Category: Neurology Tags: J Clin Neurol Source Type: research

Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Abstract Dabigatran, a direct thrombin inhibitor and activated factor X inhibitors, rivaroxaban and apixaban, used in the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF), have several advantages over vitamin K antagonists (VKAs). The non-vitamin K oral anticoagulants (NOACs) have been shown to reduce the risk of intracranial bleedings by 50%. The current review summarizes the available data on the epidemiology, mechanisms and treatment of intracranial bleedings observed on oral anticoagulation with the focus on the specificity of NOACs in this context. PMID: 260...
Source: Neurologia i Neurochirurgia Polska - May 1, 2015 Category: Neurology Authors: Łukasik M, Zawilska K, Undas A Tags: Neurol Neurochir Pol Source Type: research

Impact of dabigatran on platelet function and fibrinolysis
We sought to evaluate the potential enhanced fibrinolytic and antiplatelet activity of dabigatran etexilate (DE) due to decreased thrombin levels in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation (NVAF).
Source: Journal of the Neurological Sciences - July 22, 2015 Category: Neurology Authors: Argirios E. Tsantes, Elias Kyriakou, Stefanos Bonovas, Maria Chondrogianni, Christina Zompola, Chrissoula Liantinioti, Athina Simitsi, Aristeidis H. Katsanos, Maria Atta, Ignatios Ikonomidis, Violetta Kapsimali, Petros Kopterides, Georgios Tsivgoulis Source Type: research

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgroup of patients that could be either over-treated, risking bleeding, or under-treated, risking embolism. Additional post-marketing data lends support to the favorable therapeutic profile of dabigatran but at the same time raises doubts about patient characteristics such as weight, age, renal function and their ...
Source: Therapeutic Advances in Neurological Disorders - October 27, 2015 Category: Neurology Authors: Safouris, A., Triantafyllou, N., Parissis, J., Tsivgoulis, G. Tags: Reviews Source Type: research

The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage
Conclusion In this small case series, reversal of NOAC with FEIBA was not associated with ICH expansion or any thrombotic or hemorrhagic complications.
Source: Neurocritical Care - November 6, 2015 Category: Neurology Source Type: research

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
Conclusions: In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.Case Rep Neurol 2016;8:224 –228
Source: Case Reports in Neurology - October 31, 2016 Category: Neurology Source Type: research

Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients —Analysis of Pharmaceuticals and Medical Devices Agency Data
Two forms of direct oral anticoagulant (DOAC) have recently been introduced: direct thrombin inhibitors (DTI; e.g., dabigatran) and factor Xa inhibitors (FXa; e.g., rivaroxaban and apixaban). Despite the advantages of DOACs over warfarin with regard to cerebrovascular complications, those associated with DOACs have been reported with the increasing use of DOACs. Nevertheless, little is known about real-world comparative efficacy and safety of DOACs.
Source: Journal of Stroke and Cerebrovascular Diseases - February 3, 2017 Category: Neurology Authors: Yasuo Terayama Source Type: research

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis
Source: Journal of Neurology - February 5, 2017 Category: Neurology Source Type: research

Thrombocytopenia induced by dabigatran: two case reports
Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. heparin) are widely used to prevent thromboembolic disorders (e.g. myocardial infarction, venous thromboembolism, and stroke). These ...
Source: BMC Neurology - June 29, 2017 Category: Neurology Authors: Hyun Goo Kang, Seung Jae Lee, Ji Yeon Chung and Jin Sung Cheong Source Type: research

Severe Vasospasm of the Middle Cerebral Artery after Mechanical Thrombectomy Due to Infective Endocarditis: An Autopsy Case
We describe a case of middle cerebral artery occlusion due to IE, which caused severe vasospasm and reocclusion after mechanical thrombectomy (MT). We present the pathologic findings of the occluded middle cerebral artery and investigate the precautions to be taken while performing MT due to IE. A 72-year-old man with atrial fibrillation treated with dabigatran presented with right hemiparesis and aphasia.
Source: Journal of Stroke and Cerebrovascular Diseases - June 29, 2017 Category: Neurology Authors: Wataru Nishino, Yosuke Tajima, Toru Inoue, Michihiro Hayasaka, Bi Katsu, Koichi Ebihara, Daisuke Kawauchi, Masaaki Kubota, Sumio Suda Tags: Case Studies Source Type: research

Cerebral Microbleeds in Murine Amyloid Angiopathy Basic Sciences
Conclusions—Anticoagulation with warfarin or dabigatran for 3 to 4 months does not promote the formation of CMBs in aged APP23 mice. Nevertheless, warfarin but not dabigatran is associated with a higher risk of extensive intracerebral hemorrhage, suggesting that this model may allow preclinical safety evaluation of antithrombotic therapies.
Source: Stroke - July 24, 2017 Category: Neurology Authors: Marilena Marinescu, Li Sun, Marc Fatar, Andreas Neubauer, Lothar Schad, Joanne van Ryn, Lorenz Lehmann, Roland Veltkamp Tags: Animal Models of Human Disease, Basic Science Research, Translational Studies Original Contributions Source Type: research

Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
This study aims to observe the effectiveness and safety of idarucizumab in dabigatran-treated patients with severe bleeding or requiring surgery in Taiwan.
Source: Journal of Stroke and Cerebrovascular Diseases - November 6, 2017 Category: Neurology Authors: Li-Kai Tsai, Huey-Juan Lin, Su-Kiat Chua, Pen-Chih Liao, Yuan-Po Yang, Ping-Chen Chou, Chun-Wei Lee, Mao-Jen Lin, Hsi-Ming Chen, Jung-Tze Yeh, Yi-Heng Li Tags: Case Studies Source Type: research

Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis
Source: Journal of Neurology - August 16, 2018 Category: Neurology Source Type: research

Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil
Conclusion: The dabigatran group had a lower frequency of minor bleeding and number of medical appointments than the warfarin group, without more embolic events or major bleeding.RESUMO Objetivos: Comparar varfarina e dabigatrana para preven ção de eventos tromboembólicos em pacientes com fibrilação atrial não valvar ou flutter (FA). Métodos: Coorte retrospectiva de pacientes com FA em uso de varfarina ou dabigatrana em serviço especializado no Brasil. Resultados: Foram avaliados 112 pacientes (média idade 65,5), com 55,3% no grupo varfarina. A mediana do tempo de seguimento foi de 1,9 anos para o grupo varfarina ...
Source: Arquivos de Neuro-Psiquiatria - February 21, 2019 Category: Neurology Source Type: research

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
Maren Hieber, Juergen Bardutzky
Source: Frontiers in Neurology - March 15, 2019 Category: Neurology Source Type: research